$86 Million

Raptor Pharmaceutical Corp

Follow-on Offering

Bookrunner, April 2015

Provider of bio-pharmaceutical therapies intended to treat diseases that are debilitating and life-threatening. The company's bio-pharmaceutical therapies focuses on developing and commercializing therapies to treat debilitating and often fatal diseases for Huntington's disease, non-fatty liver disease, primary liver cancer & other cancers.